Andrew R. Hyman

Andrew R. Hyman

Corporate Officer/Principal chez Protez Pharmaceuticals, Inc.

Finance
Consumer Services
Health Technology

Profil

Prior to joining L Capital Partners, Dr. Hyman was a healthcare analyst at Columbus Circle Investors, a long-short equity hedge fund covering large-cap pharmaceuticals, biotechnology and life sciences companies.
He also worked in business development at Celera Genomics Group.
Dr. Hyman completed his Nephrology and Kidney Transplantation Fellowship at the University of Toronto and Cornell University.
He was on staff as the Associate Medical Director of the Kidney-Pancreas Transplant Program at the Toronto General Hospital.
His research interests focused on the prevention of delayed graft function post kidney transplantation and the effects of anti-rejection drugs on growth factor signaling.
He has received two Canadian National Science Research awards and has authored several peer-reviewed publications.
Dr. Hyman holds an M.D.
with Honors from the University of Toronto, a BSc.
with High Distinction from McGill University and an MBA from The Wharton School of the University of Pennsylvania.
Dr. Hyman is currently an active board observer of Protez, Cenerx and ProRhythm.

Postes actifs de Andrew R. Hyman

SociétésPosteDébut
Corporate Officer/Principal -
Tous les postes actifs de Andrew R. Hyman

Anciens postes connus de Andrew R. Hyman

SociétésPosteFin
Analyste en capital-investissement 30/06/2007
Analyst-Equity -
Analyst-Equity -
Voir l'expérience en détail de Andrew R. Hyman

Formation de Andrew R. Hyman

McGill University Undergraduate Degree
University of Toronto Doctorate Degree
University of Pennsylvania Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Andrew R. Hyman

Relations

7

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées4

Finance

Finance

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Andrew R. Hyman